"Bronchodilator Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that cause an increase in the expansion of a bronchus or bronchial tubes.
| Descriptor ID |
D001993
|
| MeSH Number(s) |
D27.505.696.663.050.110 D27.505.954.796.050.100
|
| Concept/Terms |
Bronchodilator Agents- Bronchodilator Agents
- Agents, Bronchodilator
- Bronchial-Dilating Agents
- Agents, Bronchial-Dilating
- Bronchial Dilating Agents
- Bronchodilators
Broncholytic Effect- Broncholytic Effect
- Effect, Broncholytic
- Broncholytic Effects
- Effects, Broncholytic
Bronchodilator Effect- Bronchodilator Effect
- Effect, Bronchodilator
- Bronchodilator Effects
- Effects, Bronchodilator
|
Below are MeSH descriptors whose meaning is more general than "Bronchodilator Agents".
Below are MeSH descriptors whose meaning is more specific than "Bronchodilator Agents".
This graph shows the total number of publications written about "Bronchodilator Agents" by people in this website by year, and whether "Bronchodilator Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 0 | 1 |
| 2005 | 0 | 2 | 2 |
| 2006 | 1 | 1 | 2 |
| 2007 | 1 | 3 | 4 |
| 2009 | 0 | 1 | 1 |
| 2011 | 1 | 1 | 2 |
| 2012 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2016 | 5 | 0 | 5 |
| 2017 | 51 | 34 | 85 |
| 2018 | 47 | 24 | 71 |
| 2019 | 21 | 9 | 30 |
| 2020 | 2 | 1 | 3 |
| 2021 | 2 | 2 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Bronchodilator Agents" by people in Profiles.
-
Two cases of chronic obstructive pulmonary disease evaluated by dynamic-ventilatory digital radiography for pulmonary function and assessment of treatment efficacy. Respir Investig. 2021 Nov; 59(6):871-875.
-
Praxis (Bern 1994). 2021 08; 110(10):595-596.
-
Inhaled Budesonide Reduces the Risk of Emergency Department Evaluation or Hospitalization in Early COVID-19. Am Fam Physician. 2021 08 01; 104(2):207-208.
-
Aerosol delivery systems for treating obstructive airway diseases during the SARS-CoV-2 pandemic. Intern Emerg Med. 2021 11; 16(8):2035-2039.
-
Is inhaled budesonide an effective treatment for patients with mild early symptoms of COVID-19? CJEM. 2021 09; 23(5):611-612.
-
[Inhaled budesonide in the treatment of COVID-19]. Internist (Berl). 2021 Aug; 62(8):887-889.
-
Revefenacin, a once-daily, long-acting muscarinic antagonist, for nebulized maintenance therapy in patients with chronic obstructive pulmonary disease. Am J Health Syst Pharm. 2021 06 23; 78(13):1184-1194.
-
Inhaled bronchodilators use and clinical course of adult inpatients with Covid-19 pneumonia in Spain: A retrospective cohort study. Pulm Pharmacol Ther. 2021 08; 69:102007.
-
[Inhaled nitric oxide and prone position as a rescue therapy for severe hypoxemia in an infant with COVID-19 pneumonia]. Andes Pediatr. 2021 Jun; 92(3):483-484.
-
2021 American Thoracic Society International Conference. Lancet Respir Med. 2021 07; 9(7):e65-e66.